Drugs that contain Spironolactone
1. Carospir patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10660907 | CMP DEV LLC | Spironolactone aqueous compositions |
Oct, 2036
(12 years from now) | |
| US10624906 | CMP DEV LLC | Spironolactone aqueous compositions |
Oct, 2036
(12 years from now) | |
| US9757394 | CMP DEV LLC | Spironolactone aqueous formulations |
Oct, 2036
(12 years from now) | |
| US10888570 | CMP DEV LLC | Spironolactone aqueous compositions |
Oct, 2036
(12 years from now) | |
| US11389461 | CMP DEV LLC | Spironolactone aqueous compositions |
Oct, 2036
(12 years from now) | |
| US10493083 | CMP DEV LLC | Spironolactone aqueous compositions |
Oct, 2036
(12 years from now) | |
| US11491166 | CMP DEV LLC | Spironolactone aqueous compositions |
Oct, 2036
(12 years from now) | |
| US11395828 | CMP DEV LLC | Spironolactone aqueous compositions |
Oct, 2036
(12 years from now) | |
Market Authorisation Date: 04 August, 2017
Treatment: Carospir is indicated for treatment of nyha class iii-iv heart failure and reduced ejection fraction to increase survival, manage edema, and to reduce the need for hospitalization for heart failure; C...
Dosage: SUSPENSION;ORAL
How can I launch a generic of CAROSPIR before it's drug patent expiration?
More Information on Dosage
CAROSPIR family patents
